Reported Earlier, Medicinova Announces Abstract Regarding Results Of A Clinical Trial Of MN-166 In Glioblastoma Accepted For Presentation At The 2024 ASCO

4/3/24 2:45:26 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MNOV alert in real time by email

Abstract Number: 2106

Title: Phase 1b/2a study evaluating the combination of MN-166 (ibudilast) and temozolomide in patients with newly diagnosed and recurrent glioblastoma (GBM)

Session Title: Rapid Oral Abstract – Central Nervous System Tumors

Session Date: June 2, 2024

Session Time: 11:30 AM – 1:00 PM

Get the next $MNOV alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MNOV

Date	Price Target	Rating	Analyst

More analyst ratings

$MNOV
Press Releases

Fastest customizable press release news feed in the world

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders
LA JOLLA, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) focused on development of novel anti-inflammatory treatments for neurodegenerative diseases, malignant brain cancers, and metabolic diseases, provides shareholders a corporate update in the following Letter to Stockholders from CEO Yuichi Iwaki, M.D., Ph.D.: To our esteemed stockholders, Since its founding, MediciNova has been clear in its mission to deliver new treatment options to the patients suffering with unmet medical needs. In service of that mission, we
11/19/24 9:00:00 AM ET
$MNOV
Biotechnology: Pharmaceutical Preparations
Health Care
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
LA JOLLA, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a pending patent application for MN-001 (Tipelukast) to cover "Method to Decrease Triglyceride Synthesis in a Liver of a Subject." The allowed claims cover a groundbreaking method for decreasing triglyceride synthesis in the liver by administering MN-001 (Tipelukast) or its metabolite or pharmaceutically acceptable salt. This method is particularly beneficial for subje
11/14/24 6:00:00 PM ET
$MNOV
Biotechnology: Pharmaceutical Preparations
Health Care
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
LA JOLLA, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it was notified by Sanofi that the Sanofi/Novartis litigation was settled. Accordingly, MediciNova is entitled to receive a certain amount of monetary damages through this settlement. Further details will be provided as they become available. Yuichi Iwaki, M.D., Ph.D., MediciNova CEO commented, "The successful resolution of the Sanofi-Novartis litigation and the resulting monetary damages due to MediciNova both validates the value of our intellectual p
11/11/24 6:00:00 PM ET
$MNOV
Biotechnology: Pharmaceutical Preparations
Health Care

Reported Earlier, Medicinova Announces Abstract Regarding Results Of A Clinical Trial Of MN-166 In Glioblastoma Accepted For Presentation At The 2024 ASCO

Chat with this insight

Recent Analyst Ratings for
$MNOV

$MNOV
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Maxim Group initiated coverage on MediciNova with a new price target

Maxim Group initiated coverage on MediciNova with a new price target

$MNOV
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Nagao Hideki

SEC Form 4 filed by Director Lemerond Nicole

SEC Form 4 filed by Director Beaver Carolyn

$MNOV
Press Releases

Fastest customizable press release news feed in the world

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

$MNOV
SEC Filings

SEC Form 10-Q filed by Medicinova Inc

SEC Form 10-Q filed by Medicinova Inc

Medicinova Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

$MNOV
Market Insights

Live Market Insights

MediciNova Has Received A Notice Of Allowance From The US Patent And Trademark Office For A Pending Patent Application Covering MN-166 (Ibudilast) For The Prevention Of Metastasis In Various Cancers

MediciNova Presents New Data And Results Of Phase 1b/2a Clinical Trial Of MN-166 At ASCO Meeting

MediciNova Receives Notice Of Allowance From US PTO For Pending Patent Application Which Covers MN-166 (Ibudilast) For Prevention Of Metastasis Of Eye Cancer

$MNOV
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by Medicinova Inc (Amendment)

Reported Earlier, Medicinova Announces Abstract Regarding Results Of A Clinical Trial Of MN-166 In Glioblastoma Accepted For Presentation At The 2024 ASCO

Chat with this insight

Recent Analyst Ratings for $MNOV

$MNOV Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Maxim Group initiated coverage on MediciNova with a new price target

Maxim Group initiated coverage on MediciNova with a new price target

$MNOV Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Nagao Hideki

SEC Form 4 filed by Director Lemerond Nicole

SEC Form 4 filed by Director Beaver Carolyn

$MNOV Press Releases

Fastest customizable press release news feed in the world

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

$MNOV SEC Filings

SEC Form 10-Q filed by Medicinova Inc

SEC Form 10-Q filed by Medicinova Inc

Medicinova Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

$MNOV Market Insights

Live Market Insights

MediciNova Has Received A Notice Of Allowance From The US Patent And Trademark Office For A Pending Patent Application Covering MN-166 (Ibudilast) For The Prevention Of Metastasis In Various Cancers

MediciNova Presents New Data And Results Of Phase 1b/2a Clinical Trial Of MN-166 At ASCO Meeting

MediciNova Receives Notice Of Allowance From US PTO For Pending Patent Application Which Covers MN-166 (Ibudilast) For Prevention Of Metastasis Of Eye Cancer

$MNOV Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by Medicinova Inc (Amendment)

Recent Analyst Ratings for
$MNOV

$MNOV
Analyst Ratings

$MNOV
Insider Trading

$MNOV
Press Releases

$MNOV
SEC Filings

$MNOV
Market Insights

$MNOV
Large Ownership Changes